J Gynecol Oncol.  2019 Jan;30(1):e13. 10.3802/jgo.2019.30.e13.

The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification

Affiliations
  • 1Department of Gynecology, Campus Virchow Clinic, Charite Medical University, Berlin, Germany.
  • 2Nuffield Department of Obstetrics and Gynecology, University of Oxford, Oxford, United Kingdom.
  • 3Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. Xiaojunchen2013@sina.com
  • 4Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, China.
  • 5Cervical disease diagnosis and treatment center, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
  • 6Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.

Abstract


OBJECTIVES
Although patients with grade I and II endometrioid endometrial adenocarcinoma (EEA) are considered with good prognosis, among them 15%-25% died in 5 years. It is still unknown whether integrating estrogen receptor (ER) and progesterone receptor (PR) into clinical risk stratification can help select high-risk patients with grade I-II EEA. This study was to investigate the prognostic value of ER and PR double negativity (ER/PR loss) in grade I-II EEA, and the association between ER/PR loss and The Cancer Genome Atlas (TCGA) classification.
METHODS
ER and PR were assessed by immunohistochemistry on hysterectomy specimens of 903 patients with grade I-II EEA. ER and PR negativity were determined when < 1% tumor nuclei were stained. Gene expression data were obtained from the TCGA research network.
RESULTS
Compared with ER or PR positive patients (n=868), patients with ER/PR loss (n=35) had deeper myometrial infiltration (p=0.012), severer FIGO stage (p=0.004), and higher rate of pelvic lymph node metastasis (p=0.020). In univariate analysis, ER/PR loss correlated with a shorter progression-free survival (PFS; hazard ratio [HR]=5.25; 95% confidence interval [CI]=2.21-12.52) and overall survival (OS; HR=7.59; 95% CI=2.55-22.60). In multivariate analysis, ER/PR loss independently predicted poor PFS (HR=3.77; 95% CI=1.60-10.14) and OS (HR=5.56; 95% CI=1.37-22.55) for all patients, and poor PFS for patients in stage IA (n=695; HR=5.54; 95% CI=1.28-23.89) and stage II-IV (n=129; HR=5.77; 95% CI=1.57-21.27). No association was found between ER/PR loss and TCGA classification.
CONCLUSION
Integrating ER/PR evaluation into clinical risk stratification may improve prognosis for grade I-II EEA patients.

Keyword

Endometrial Cancer; Endometrioid Carcinoma; Low-Grade; Estrogen Receptor; Progesterone Receptor; Biomarker

MeSH Terms

Adenocarcinoma*
Carcinoma, Endometrioid
Classification
Disease-Free Survival
Endometrial Neoplasms
Estrogens*
Female
Gene Expression
Genome
Humans
Hysterectomy
Immunohistochemistry
Lymph Nodes
Multivariate Analysis
Neoplasm Metastasis
Progesterone*
Prognosis
Receptors, Progesterone*
Estrogens
Progesterone
Receptors, Progesterone
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr